Bristol Myers Squibb drops Prothena's PRX019 after internal reviewOct 29PartnershipBristol Myers SquibbProthena Corp Public Ltd Co
BMS registers Phase 1 CAR T cell trial in kidney cancer; adds mavacamten real-world studyOct 1Weekly roundup, 5 itemsBristol Myers SquibbgolcadomideUpdated
BMS registers Phase 2 depression trial for BMS-986511; adds Alzheimer's PK study for BMS-986446Aug 21Weekly roundup, 6 itemsBristol Myers Squibbentecavir
Prothena reports Q2 2026 results, updates year-end cash guidance to $259 millionAug 6Quarterly updateProthena Corp Public Ltd Co